← Back to all trials
Active Not Recruiting
NCT03446521
AGRA Before and After Liver Transplantation
Conditions: Liver Cirrhosis
Sex: All
Ages: 18 Years – 80 Years
Healthy volunteers: No
Enrollment: 76
Sponsor: Medical University of Graz
Location: Department of Internal Medicine, Medical University of Geraz Graz
Summary
The immune system is impaired in liver cirrhotic patients, which is associated with a high risk for bacterial infections and worse outcome. A novel biomarker, acellular growth retardation ability (AGRA), can predict the development of severe infections in patients with liver cirrhosis and therefore identify patients at risk. It is still unclear, how this biomarker develops after liver transplantation and how valid its predictions are for post-operative infections. Therefore, AGRA will be measured before and after liver transplantation and predictive merit of AGRA for post-transplant infections will be tested.
Eligibility Criteria
Inclusion Criteria:
* Patients between 18-80 years
* Listed for liver transplantation (for recipients)
* Liver recipient is included in the study (for donors)
* Informed consent
Exclusion Criteria:
* Antibiotic therapy with substances active against E. coli at the scheduled blood sampling
Source: ClinicalTrials.gov (NCT03446521). StuddyBuddy aggregates publicly available trial information.
